# Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients

> **NCT05185817** · PHASE2 · UNKNOWN · sponsor: **Tehran University of Medical Sciences** · enrollment: 100 (estimated)

## Conditions studied

- Hematopoietic Stem Cell Transplantation (HSCT)
- COVID-19 Vaccines
- Immune System Tolerance

## Interventions

- **BIOLOGICAL:** Pasocovac vaccine

## Key facts

- **NCT ID:** NCT05185817
- **Lead sponsor:** Tehran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05185817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05185817, "Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05185817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*